Sign in to view content

Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS

Video
Published 2024

Related

Correlation Of Ganglion Cell Layer Damage And Diabetic Macular Ischemia Using OCT Angiography and Their Relationship With Visual Acuity in Diabetes
Dilraj S Grewal, MD, FASRS
On Demand Cases, Courses, and Papers
2017
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Updates from the Field
2021
Complications, Compliance, and 2-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage
Dennis M. Marcus, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more